Tradition Wealth Management LLC cut its holdings in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.6% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,919 shares of the company’s stock after selling 74 shares during the quarter. Tradition Wealth Management LLC’s holdings in Johnson & Johnson were worth $2,112,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently modified their holdings of the company. Norges Bank bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $4,172,929,000. BlackRock Inc. raised its holdings in shares of Johnson & Johnson by 2.6% in the 4th quarter. BlackRock Inc. now owns 200,021,352 shares of the company’s stock valued at $34,217,654,000 after purchasing an additional 4,982,885 shares during the period. GQG Partners LLC raised its holdings in shares of Johnson & Johnson by 1,109.4% in the 4th quarter. GQG Partners LLC now owns 3,954,383 shares of the company’s stock valued at $676,375,000 after purchasing an additional 3,627,424 shares during the period. State Street Corp raised its holdings in shares of Johnson & Johnson by 1.8% in the 4th quarter. State Street Corp now owns 144,677,639 shares of the company’s stock valued at $24,750,004,000 after purchasing an additional 2,492,359 shares during the period. Finally, Swiss National Bank raised its holdings in shares of Johnson & Johnson by 14.0% in the 1st quarter. Swiss National Bank now owns 11,402,516 shares of the company’s stock valued at $2,020,868,000 after purchasing an additional 1,396,500 shares during the period. 68.78% of the stock is owned by institutional investors.
Insider Buying and Selling at Johnson & Johnson
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the sale, the executive vice president now owns 71,311 shares in the company, valued at $12,336,803. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.35% of the company’s stock.
Johnson & Johnson Stock Performance
NYSE JNJ opened at $164.27 on Friday. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $431.90 billion, a price-to-earnings ratio of 23.91, a P/E/G ratio of 3.15 and a beta of 0.59. The firm’s 50 day simple moving average is $173.07 and its 200 day simple moving average is $174.34. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69.
Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.02. The business had revenue of $24.02 billion for the quarter, compared to analyst estimates of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.14%. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same quarter last year, the business posted $2.48 EPS. As a group, research analysts expect that Johnson & Johnson will post 10.05 earnings per share for the current fiscal year.
Johnson & Johnson Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be given a $1.13 dividend. The ex-dividend date of this dividend is Monday, August 22nd. This represents a $4.52 dividend on an annualized basis and a yield of 2.75%. Johnson & Johnson’s dividend payout ratio is currently 65.79%.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on the stock. Morgan Stanley upped their target price on shares of Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a report on Friday, July 8th. Wells Fargo & Company increased their price target on shares of Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a report on Wednesday, July 13th. Citigroup lowered their price target on shares of Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 17th. Finally, Daiwa Capital Markets assumed coverage on shares of Johnson & Johnson in a report on Wednesday, June 22nd. They issued an “outperform” rating on the stock. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $189.89.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.